Human erythropoietic protoporphyria is an inherited disorder of the heme metabolic pathway caused by defects in the gene for ferrochelatase, the terminal enzyme of the pathway that catalyzes chelation of ferrous iron into protoporphyrin IX to form heme. Mutation analysis was performed for families with erythropoietic protoporphyria and four novel frameshift mutations were identified. Two of the mutations, 205insA and 215insT in exon 3 of the ferrochelatase gene, are single bp insertions. The other two, 400delA in exon 4 and 678delG in exon 6, are single bp deletions. All of the mutations result in premature termination codons downstream shortly after the mutation sites, and in one case the premature termination codon caused by 400delA was also shown to reduce mRNA level via nonsense-mediated mRNA decay.

Download full-text PDF

Source
http://dx.doi.org/10.1111/1523-1747.ep12338217DOI Listing

Publication Analysis

Top Keywords

erythropoietic protoporphyria
12
protoporphyria novel
8
novel frameshift
8
frameshift mutations
8
ferrochelatase gene
8
premature termination
8
mutations
4
mutations ferrochelatase
4
gene human
4
human erythropoietic
4

Similar Publications

The histamine pathway is a target to treat hepatic experimental erythropoietic protoporphyria.

Cell Mol Gastroenterol Hepatol

January 2025

Center for Advanced Biotechnology and Medicine, Rutgers University, Piscataway, NJ, USA. Electronic address:

Background & Aims: Erythropoietic protoporphyria (EPP) is caused by mutations in ferrochelatase which inserts iron into protoporphyrin-IX (PP-IX) to generate heme. EPP is characterized by PP-IX accumulation, skin photosensitivity, cholestasis, and end-stage liver disease. Despite available drugs that address photosensitivity, treatment of EPP-related liver disease remains an unmet need.

View Article and Find Full Text PDF
Article Synopsis
  • Erythropoietic protoporphyria (EPP) and X-linked protoporphyria (XLP) are rare genetic disorders that lack comprehensive management data, prompting a study of their characteristics and treatment in real-world U.S. settings.
  • The study reviewed medical records of 299 EPP and 91 XLP patients, revealing a mean diagnosis delay of 2.9 years and highlighting common pre-diagnostic tests and lifestyle recommendations.
  • Findings indicated a significant number of healthcare visits post-diagnosis and identified unmet needs, such as the need for quicker diagnoses, effective symptom relief, and better prevention of phototoxic reactions.
View Article and Find Full Text PDF

Activation of the melanocortin 1 receptor (MC1R) mediates melanogenesis in melanocytes, anti-inflammatory effects in inflammatory cells, and antifibrotic effects in fibroblasts. Thus, MC1R agonists are expected to be beneficial for treating skin, autoimmune, inflammatory, and fibrotic diseases. Afamelanotide, an α-melanocyte-stimulating hormone (α-MSH) analogue MC1R agonist, is used clinically for treating erythropoietic protoporphyria (EPP) as a subcutaneous implant formulation.

View Article and Find Full Text PDF

Inhibition of ABCG2 prevents phototoxicity in a mouse model of erythropoietic protoporphyria.

Nat Commun

December 2024

Center for Pharmacogenetics, Department of Pharmaceutical Sciences, School of Pharmacy, University of Pittsburgh, Pittsburgh, PA, USA.

Article Synopsis
  • Erythropoietic protoporphyria (EPP) is a genetic disorder that causes painful skin reactions when exposed to light, with few treatment options available.
  • Researchers developed oral inhibitors of the ABCG2 transporter, which helps remove protoporphyrin IX from cells, as a new therapeutic approach.
  • In a mouse model of EPP, these inhibitors were successful in reducing protoporphyrin IX levels and preventing phototoxic reactions, offering a promising new treatment strategy.
View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!